Top Analyst Reports For Oracle, U.S. Bancorp & Enterprise Products
Zacks Investment Research | Mar 14, 2019 01:34AM ET
Thursday, March 14, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), U.S. Bancorp (USB) and Enterprise Products (EPD). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Oracle’s shares have underperformed the Zacks Computer Software industry in the past year, gaining +1.3% vs. +17.3%. Oracle is one of the largest enterprise-grade database, middleware and application software providers. The Zacks analyst thinks the company is benefiting from strong adoption of its cloud-based solutions, comprising Fusion ERP and Fusion HCM, among others. Partnerships with the likes of Accenture (NYSE:ACN) are helping the company rapidly expand its cloud-base clientele.
Also, anticipated strong demand for the next-generation autonomous database supported by machine learning will boost competitive position against Amazon (NASDAQ:AMZN) Web Services (AWS). Nonetheless, stiff competition in the cloud market from dominant players is anticipated to limit margin expansion.
Lower hardware volumes are anticipated to hurt top-line growth, consequently keeping margins under pressure. Additionally, integration risks from buyouts remain a concern.
(You can ).
Shares of U.S. Bancorp have outperformed the Zacks Major Banks industry over the past six months, losing -4.7% vs -6.7%. The company possesses an impressive earnings surprise history, beating expectations in all the trailing four quarters.
The Zacks analyst thinks U.S. Bancorp's prospects will likely get support from its solid business model, core franchise, lower tax rate, rising interest rate and diverse revenue streams. Also, its organic growth remains solid and will likely benefit from the improving economic scenario.
U.S. Bancorp remains well poised to grow through acquisitions. However, escalating expenses due to its ongoing investments in technology and likely increase in legal expenses remain concerns.
(You can ).
Enterprise Products’ shares have gained +13.6% over the past three months, outperforming the Zacks Oil Production Pipeline MLP industry advanced by +11.9%. Enterprise Products Partners boasts of an extensive network of pipeline that spreads across nearly 50,000 miles.
Get The News You Want
Importantly, the pipeline network is connected to every major U.S. shale play and provides services to producers and users of commodities by transporting gas, liquids and refined products. The Zacks analyst thinks Enterprise’s $5.1-billion pipeline of fee-oriented midstream projects will enable it to enjoy above-average growth in distributable cash flow (DCF) over the next two years, expanding its distribution coverage ratio.
However, turnaround-related costs from Seminole fractionators hurt Enterprise’s fractionation business. Also, the persistent rise in operating expenses has been affecting the partnership’s bottom line. Enterprise’s balance sheet is more levered than the industry it belongs to. Therefore, the stock warrants a cautious stance.
(You can ).
Other noteworthy reports we are featuring today include Intuitive Sherwin-Williams (SHW), PPL Corp. (PPL) and Cintas (CTAS).
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst likes the traffic increase due to strong demand for air travel. Efforts to modernize its fleet are also encouraging.
Per the Zacks analyst, Cimarex will significantly grow on the back of the oil resources acquired from Resolute Energy.
The Zacks analyst likes United Therapeutics' efforts to develop new delivery mechanisms for Remodulin and expanded indications for other PAH drugs like Orenitram and Tyvaso amid increased competition.
Per the Zacks analyst, new store openings, expansion of online presence and strategic collaborations aid Advance Auto's growth.
The Zacks analyst thinks Southwestern's investments in high-return areas such as Appalachia are noteworthy.
Per the Zacks analyst, growing revenues driven by strong organic and inorganic growth has led to significant growth.
Per the Zacks analyst, Legg Mason's strategic acquisitions have resulted in diversified product offerings and expansion in market share.
The Zacks analyst likes the traffic increase due to strong demand for air travel. Efforts to modernize its fleet are also encouraging.
Per the Zacks analyst, Cimarex will significantly grow on the back of the oil resources acquired from Resolute Energy.
The Zacks analyst likes United Therapeutics' efforts to develop new delivery mechanisms for Remodulin and expanded indications for other PAH drugs like Orenitram and Tyvaso amid increased competition.
Per the Zacks analyst, new store openings, expansion of online presence and strategic collaborations aid Advance Auto's growth.
The Zacks analyst thinks Southwestern's investments in high-return areas such as Appalachia are noteworthy.
Per the Zacks analyst, growing revenues driven by strong organic and inorganic growth has led to significant growth.
Per the Zacks analyst, Legg Mason's strategic acquisitions have resulted in diversified product offerings and expansion in market share.
New Upgrades/h6
The Zacks analyst believes that massive oil equivalent reserves in the deepwater Gulf of Mexico will help W&T Offshore boost production volumes.
Per the Zacks analyst, Omnicell's recently-inked deals for both the XR2 and the IVX Workflow products look strategic. The company continues to see solid uptake of Omnicell XT.
Per the Zacks analyst, HCP will likely gain from its efforts to improve portfolio quality and operator mix. Focus on medical office and life-science properties is also encouraging.
The Zacks analyst believes that massive oil equivalent reserves in the deepwater Gulf of Mexico will help W&T Offshore boost production volumes.
Per the Zacks analyst, Omnicell's recently-inked deals for both the XR2 and the IVX Workflow products look strategic. The company continues to see solid uptake of Omnicell XT.
Per the Zacks analyst, HCP will likely gain from its efforts to improve portfolio quality and operator mix. Focus on medical office and life-science properties is also encouraging.
New Downgrades/h6
According to the Zacks analyst, higher raw materials costs and sizable charges related to the Valspar acquisition will weigh on Sherwin-Williams' bottom line in 2019.
Per the Zacks analyst, stringent regulation, unplanned outages and high-debt levels amid rising interest rates are headwinds for PPL Corporation (NYSE:PPL).
Per the Zacks analyst, Cintas' revenue growth is being dampened by a rise in operating expenses due to increase in commodity costs. High debt level is putting pressure on the company's profitability.
According to the Zacks analyst, higher raw materials costs and sizable charges related to the Valspar acquisition will weigh on Sherwin-Williams' bottom line in 2019.
Per the Zacks analyst, stringent regulation, unplanned outages and high-debt levels amid rising interest rates are headwinds for PPL Corporation (NYSE:PPL).
Per the Zacks analyst, Cintas' revenue growth is being dampened by a rise in operating expenses due to increase in commodity costs. High debt level is putting pressure on the company's profitability.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.